Coordinatore | UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 13˙016˙641 € |
EC contributo | 9˙998˙092 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-B |
Funding Scheme | CP-IP |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-04-01 - 2014-03-31 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | coordinator | 1˙622˙507.00 |
2 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 1˙014˙297.00 |
3 |
FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA
Organization address
address: CARRETERA DE CANYET contact info |
ES (BARCELONA) | participant | 949˙630.00 |
4 |
ASSOCIATION DE RECHERCHE EN VIROLOGIE ET DERMATOLOGIE
Organization address
address: Place Louis Armand 4 contact info |
FR (Paris) | participant | 938˙180.00 |
5 |
INFORMA SRL
Organization address
address: VIA DEL COMMERCIO 36 contact info |
IT (ROMA) | participant | 789˙632.00 |
6 |
THE D.I. IVANOVSKY INSTITUTE OF VIROLOGY OF THE MINISTRY OF THE HEALTHOF THE RUSSIAN FEDERATION
Organization address
address: GAMALEYA UL 16 contact info |
RU (MOSKVA) | participant | 496˙892.00 |
7 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 415˙941.00 |
8 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 382˙923.00 |
9 |
UNIVERSITE VICTOR SEGALEN BORDEAUX II
Organization address
address: RUE LEO SAIGNAT 146 contact info |
FR (BORDEAUX CEDEX) | participant | 361˙842.00 |
10 |
EuResist Network GEIE
Organization address
address: VIA LUIGI RAVA 43 contact info |
IT (ROMA RM) | participant | 318˙236.00 |
11 |
FONDAZIONE ICONA
Organization address
address: Via Vittor Pisani 16 contact info |
IT (Milano) | participant | 315˙880.00 |
12 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 309˙750.00 |
13 |
UNIVERZA V LJUBLJANI
Organization address
address: KONGRESNI TRG 12 contact info |
SI (LJUBLJANA) | participant | 295˙832.00 |
14 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 277˙999.00 |
15 |
FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS
Organization address
address: CORSO STATI UNITI 4 contact info |
IT (PADOVA) | participant | 202˙140.00 |
16 | KOBENHAVNS UNIVERSITET | DK | participant | 199˙056.00 |
17 |
ROBERT KOCH-INSTITUT
Organization address
address: Nordufer 20 contact info |
DE (Berlin) | participant | 179˙892.00 |
18 |
UNIVERSITE CHEIKH ANTA DIOP DE DAKAR
Organization address
address: Avenue Martin Luther King contact info |
SN (DAKAR FANN) | participant | 172˙080.00 |
19 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 152˙980.00 |
20 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 147˙830.00 |
21 |
INSTITUTO DE HIGIENE E MEDICINA TROPICAL
Organization address
address: Rua da Junqueira 100 contact info |
PT (LISBOA) | participant | 125˙718.00 |
22 |
Ministry of Public Health
Organization address
city: YAOUNDE contact info |
CM (YAOUNDE) | participant | 90˙000.00 |
23 |
JANSSEN INFECTIOUS DISEASES DIAGNOSTICS BVBA
Organization address
address: TURNHOUTSEWEG 30 contact info |
BE (BEERSE) | participant | 79˙705.00 |
24 |
WORLD HEALTH ORGANIZATION.
Organization address
address: Avenue Appia 20 contact info |
CH (GENEVE) | participant | 70˙000.00 |
25 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 50˙000.00 |
26 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 39˙150.00 |
27 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 0.00 |
28 |
UNIVERSITE DE BORDEAUX
Organization address
address: PLACE PEY BERLAND 35 contact info |
FR (BORDEAUX) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'CHAIN is a large scale integrating project aimed to effectively and durably combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and in heavily affected resource-poor regions in Africa. This will be achieved through our pan-European network of surveillance and basic research activities, the involvement of all main actors in the field of HIV and anti-HIV drug resistance, monitoring how resistances develop and evolve, improved understanding of mechanisms of resistance development, performing molecular epidemiology studies, providing improved and new strategies to evaluate and limit the emergence and transmission of HIV drug resistance, setting up training and dissemination activities and supporting evidence-based public health policy and action. CHAIN brings together Europe’s leading internationally recognised scientific expertise in basic science, molecular epidemiology, bioinformatics and surveillance of HIV and HIV resistance including the WHO, strong links to Eastern Europe through the existing FP6 funded cohort network Europe HIVresistance and strategic links to relevant pan-European cohort networks and national cohort networks (PENTA/ECS, CASCADE, EuroSIDA, COHERE, ICoNa, UK-CHIC, SHCS). Our balanced programme of work is informed by optimising the synergistic skills represented by the applicants, and also through harmonising with existing initiatives, that ensures lack of duplication, but rather maximises the impact of European activities. Thus, our African and Eastern European work will be linked to WHO policy, our European surveillance studies will be guided by ECDC (through our advisory board), and our clinical research will generate questions best addressed through the NEAT clinical trial network. Finally, our partnership with the key biotechnology companies in HIV resistance will ensure maximal impact of our basis research activities.'
EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations
Read MoreMultidisciplinary Approaches to Translational Research In Conduct Syndromes
Read MoreTreatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease
Read More